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Despite improvements in our understanding of pancreatic cancer and the emerging
concept of personalized medicine for the treatment of this disease, it is still the fourth
most common cause of cancer death in the western world. It is established that pancreatic
cancer is a highly heterogeneous disease with a complex tumor microenvironment. Indeed
the extensive stroma surrounding the cancer cells has been shown to be important
in promoting tumor growth and metastases, as well as sequestering chemotherapeutic
agents consequently decreasing delivery to the tumor cells. Nanotechnology has come to
the forefront in the areas of medical diagnostics, imaging, and therapeutic drug delivery.
This review will focus on the potential applications of nanotechnology for diagnosis,
imaging, and delivery of therapeutic agents for the treatment of pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is one of the most lethal cancers worldwide
with a 5-year relative survival rate of <6% (Jemal et al., 2011;
Siegel et al., 2013). Despite aggressive combinations of therapies
ranging from surgery, chemotherapy, and radiotherapy, patients
diagnosed with this malignancy have extremely high mortality
rates and poor prognosis (Vincent et al., 2011). These dismal
outcomes can in part be attributed to a lack of early diagno-
sis and inability to detect pre-cancerous pancreatic intraductal
neoplastic (PanIN) lesions, which often give rise to invasive pan-
creatic tumors (Misek et al., 2007). Currently no clinically reliable
serum biomarkers for early detection and diagnosis at an early
stage of pancreatic cancer are available (Misek et al., 2007). A
majority of pancreatic cancers are diagnosed and staged by com-
puted tomography (CT) imaging or magnetic resonance imaging
Abbreviations: PanIN, Pancreatic intraductal neoplastic lesions; PSCs, pancreatic
stellate cells; ECM, extracellular matrix; EUS, endoscopic ultrasonography; MRI,
Magnetic Resonance Imaging; MRCP, Cholangiopancretography; EPR, enhanced
permeability and retention; RNAi, RNA interference; RISC, RNA-induced silenc-
ing complex; siRNA, short-interfering RNA; Muc, Mucin; IONP, Iron oxide
nanoparticle; TfR, Transferrin Receptor; SPION, Superparamagnetic Iron Oxide
Nanoparticles.
(MRI) with a tumor detection limit of 5–8mm when the ear-
liest precursor lesions are in the microscopic range (Holzapfel
et al., 2011; Canto et al., 2012). Consequently, >80% of patients
have locally advanced or distant metastases upon diagnosis, with
chemotherapy or palliative chemotherapy being the current stan-
dard for systemic treatment (Vincent et al., 2011). Notably, only
20% of patients at the time of diagnosis are suitable for potentially
curative pancreatectomy and despite combination with adjuvant
chemotherapy, a majority of patients still develop local recur-
rences and systemic metastases that results in mortality (Hidalgo,
2010). Another contributing factor to the poor outcome of pan-
creatic cancer is that the current standard first-line therapy of
the chemotherapeutic agent gemcitabine shows only limited effi-
cacy by extending the overall survival of patients by only 6–12
weeks (Hidalgo, 2010). This is partially due to poor understand-
ing of the biology of the individual patients’ tumor, chemotherapy
resistance and the tumor microenvironment.
Nanotechnology is defined as the manipulation of organic or
inorganic materials to form structures on the scale of nanome-
ters. Recently, advances in nanotechnology have provided great
opportunities for strategies in advancing cancer diagnostics,
imaging, and therapeutic drug delivery (Schroeder et al., 2011;
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Melancon et al., 2012; Prabhu and Patravale, 2012). Nanoparticles
have the potential to not only increase the efficacy per dose
of a therapeutic or imaging contrast formulation by increasing
its bioavailability, but can also be modified for targeted selec-
tivity toward tumor cells to increase image resolution and/or
reduce off-target toxicities associated with current chemother-
apy (Ferrari, 2005). Furthermore, they show promise in treating
metastatic cancers like pancreatic cancer [see detailed review
(Schroeder et al., 2011)]. Nevertheless, in order to design effec-
tive nanoparticles to deliver either imaging contrast agents or
therapeutics (by passive or active targeting) requires a thorough
understanding of the physiological barriers specifically associ-
ated with the disease and apply nano-engineered components for
effective nanoparticle extravasation, accumulation and penetra-
tion into the tumor (Jain and Stylianopoulos, 2010). This review
highlights promising translational prospects and the challenges
of integrating nano-engineering sciences with pancreatic cancer
biology to develop nanomaterials that could enhance diagnostics,
imaging, and therapeutics against this devastating malignancy
(Table 1).
THE PANCREATIC TUMOR MICROENVIRONMENT AND ITS
ROLE IN PROMOTING CHEMOTHERAPY RESISTANCE
Desmoplasia and hypovascularity are the pathological hallmarks
of pancreatic tumors. The desmoplastic microenvironment (also
known as the stroma) can make up >90% of the tumor mass (Li
et al., 2010; Neesse et al., 2011). The stroma contains a number
of different cell types including, pancreatic stellate cells (PSCs),
endothelial cells, immune cells and dense extracellular matrix
(ECM) (Li et al., 2010; Neesse et al., 2011). Indeed, it is well
established that PSCs are the principle cell type responsible for
the production of stromal fibrosis (Apte et al., 2004; Bachem
Table 1 | Potential advantages of nanotechnology for the diagnosis
and treatment of pancreatic cancer.
Advantages of nanotechnology
in diagnostics and imaging for
pancreatic cancer
Advantages of nanotechnology
for therapy in pancreatic cancer
Increased sensitivity and specificity
compared to conventional assays
using only small amounts of patient
sample.
Increased drug delivery to tumor
cells.
Detection of early cancer
biomarkers in blood samples
(RNA/DNA, exosomes, proteins).
Increased tumor specificity via
the use of tumor cell targeting
moieties.
Monitor patient treatment response
via biomarker detection and/or
imaging.
Potential to decrease off-target
systemic drug toxicity.
Potential to non-invasively
differentiate between tumor and
stromal elements in pancreatic
cancer.
Potential to deliver therapeutics to
target and silence non-druggable
genes using RNAi inhibitors.
Increased sensitivity to detect
small local and distant metastases.
Provide increased solubility,
stability and circulation half-life for
current chemotherapeutic drugs.
et al., 2005). Importantly, the extensive fibrotic characteristic of
pancreatic cancer results in reduced intratumoral vascular den-
sity which give rise to compromised dysfunctional vessels that
cause a decrease in blood flow; inadequate venous and lym-
phatic drainage also further increases the interstitial fluid pressure
within pancreatic tumors (Koong et al., 2000; Erkan et al., 2007;
Komar et al., 2009; Olive et al., 2009). As a consequence the
stroma has been shown to play a major role in poor chemother-
apy drug delivery, penetration, and rapid metabolic inactivation
of therapeutic agents which contribute to an unusually poor
response to treatment (Olive et al., 2009; Provenzano et al., 2012).
Furthermore, the bi-directional interaction that occurs between
PSCs and the tumor cells further potentiates tumor progres-
sion, chemoresistance, invasion, and metastases (Apte et al., 2004;
Bachem et al., 2005; Vonlaufen et al., 2008; Olive et al., 2009; Xu
et al., 2010; Phillips, 2012). However, the stroma could also be
the achilles’ heel for targeted diagnostic imaging and therapeu-
tic drug therapy to ablate the microenvironment that supports
tumor growth and metastases (Phillips, 2012; Heinemann et al.,
2013). In addition, given the tumor mass comprises mainly of the
fibrotic stroma, the ECM components or PSCs residing within
the stroma could be novel targets for early diagnosis, imaging,
and targeted therapy. Examples of how nanotechnology may be
applied to advance pancreatic cancer diagnosis and treatment are
described below.
NANO-DIAGNOSTICS FOR THE EARLY DETECTION OF
PANCREATIC CANCER
The vast majority of long-term survivors of pancreatic cancer
(> than 5 years) have resectable disease upon diagnosis and are
suitable for curative surgery, suggesting early detection and inter-
vention may increase the overall survival of patients (Slavin et al.,
1999). However, currently there are no reliable serum biomark-
ers with the sensitivity and specificity to accurately detect early
pre-cancerous lesions (Goggins, 2005). This is largely due to the
lack of pancreatic cancer biomarkers able to distinguish between a
benign diseased pancreas, such is the case for chronic pancreatitis
and cancer, as both are hard to distinguish under current imaging
modalities (Erkan et al., 2012a,b). Moreover, the heterogeneous
nature of pancreatic cancer and the complex stromal microenvi-
ronment also present a challenge for potential biomarkers. Hence,
early diagnosis of pancreatic tumors may require the simulta-
neous identification of a panel of biomarkers to have greater
accuracy compared to single biomarkers.
Nano-diagnostic platforms have the potential to revolutionize
the cancer diagnostics field by developing faster, more accu-
rate, cost-effective, and reliable biomarker detection systems with
lower detection limits (Cao, 2008; Chikkaveeraiah et al., 2012;
Malhotra et al., 2012). Various electrochemical immunosensors
have also integrated nanomaterials such as magnetic particles,
gold nanoparticles, quantum dots, and carbon nanotubes to
increase their sensitivity for electrochemical detection of tumor
biomarkers(Cao, 2008; Chikkaveeraiah et al., 2012; Malhotra
et al., 2012). For instance, microfluidic biochips integrated with
highly luminescent quantum dots have shown promise as a
versatile multicolor and multiplexed bioassay(Hu et al., 2010).
This was evidenced by their ability to rapidly detect two cancer
Frontiers in Physiology | Gastrointestinal Sciences January 2014 | Volume 5 | Article 2 | 2
McCarroll et al. Therapeutic potential of nanotechnology and pancreatic cancer
biomarkers, carcinoma embryonic antigen, and α-fetoprotein,
with high selectivity and femtomolar sensitivity in human serum
(Hu et al., 2010). Recently, Chang et al. (2011) managed to design
passivated (technique used to prevent or retard non-specific back-
ground signal) nanowire biosensors to allow rapid and specific
detection of the ovarian cancer biomarkers, cancer antigen-125
and insulin-like growth factor-II directly from human whole
blood collected simply from a finger prick, withmuch lower limits
of detection compared to the clinically relevant levels for diag-
nosis (Chang et al., 2011). Others like, the NanoMonitor incor-
porated nanoporous alumina membranes onto micro-fabricated
silicon platforms allowing rapid label-free analysis of glycans from
pancreatic cancer cell lysates with high sensitivity and selectiv-
ity (Nagaraj et al., 2010). Biosensors like these could be useful
for pancreatic cancer diagnosis in the clinic by identifying other
transmembrane glycoproteins such as mucins (MUC) which are
expressed on the surface of pancreatic cancer cells and are impor-
tant regulators of tumor growth and metastases (Kaur et al.,
2013). Indeed, studies have demonstrated several members of the
MUC protein family to be overexpressed and/or aberrantly glyco-
sylated during the progression of early PanIN lesions to pancreatic
tumors in amouse transgenic model (KrasG12D;Pdx1-Cre), which
mimics the human setting for the initiation and progression of
pancreatic cancer (Rachagani et al., 2012; Remmers et al., 2013).
Nano-diagnostics could also be explored in the case of pancre-
atic cancer-induced paraneoplastic diabetes to aid early diagnosis
(Sah et al., 2013). It has been suggested that up to 85% of pan-
creatic cancer patients have diabetes or hyperglycemia which can
manifest as early as 2–3 years before the development of pan-
creatic cancer (Sah et al., 2013). Hence, nano-diagnostics which
employ the use of a combination of early cancer biomarkers
along with indicators of β cell dysfunction (resulting in worsening
type 2 diabetes and increased adrenomedullin levels) could have
potential diagnostic utility, to be explored in a large patient cohort
(Hart et al., 2011; Aggarwal et al., 2012; Sah et al., 2013). In sum-
mary, nano-diagnostics are powerful tools for cancer detection,
prevention, and diagnosis. Nano-diagnostic platforms may pro-
vide additional sensitivity with relatively small sample volumes
for biomarker detection. Furthermore, the increase in sensitivity,
specificity, and multiplex properties for the detection of can-
cer biomarkers using nano-diagnostics could also be used as
a monitoring platform to detect early recurrences or to follow
the response of patients to treatment that would otherwise be
undetectable with conventional assays.
NANOMATERIALS FOR ADVANCING PANCREATIC CANCER
IMAGING
Currently, the most accurate initial screening modalities for
the detection of pancreatic cancer are endoscopic ultrasonog-
raphy (EUS) and/or MRI cholangiopancretography (MRCP)
(Hekimoglu et al., 2008; Hyodo et al., 2012). The limitation
of current imaging-based screens is that upon identification of
potentially benign cysts/lesions, subsequent invasive evaluation
by collecting tissue biopsies (for example through fine nee-
dle aspiration) is still required to confirm diagnosis (Brand,
2001). Early diagnostics to identify carcinomas in situ like PanIN
lesions are often challenging due to the detection limit of current
radiological methods and how chronic pancreatitis masses show
similar pathological aspects (fibrotic stroma) to pancreatic can-
cer (Erkan et al., 2012a,b). Only cystic tumors are detectable at
a pre-invasive stage with conventional radiological methods due
to their large size and high contrast compared to the normal
pancreas (Erkan et al., 2012a,b). Furthermore, smaller (<1 cm)
metastatic tumor deposits in the liver and/or peritoneal cavity
may be overlooked by MRI or CT.
To improve the detection limit of MRI or CT-imaging, an
extraneous imaging agent can be administered to the patient to
enhance the imaging signals leading to the commercial devel-
opment of a large range of small organic contrast agents. For
example, more than one third of MRI scans are performed in
conjunction with a contrast imaging agent. The first generation
of organic contrast agents had some limitations (poor specificity
and rapid renal clearance) (Roberts, 1997; Kim et al., 2011). To
overcome these limitations, contrast agents have been designed
in a nanoparticle formulation (Hahn et al., 2011). The incorpo-
ration of contrast agents into nanoparticles can offer significant
advantages, such as easy functionalization by targeting moieties,
higher sensitivity compared to small organic contrast agents and
improved biodistribution. For instance, inorganic nanomateri-
als [including gold nanoparticles, and superparamagnetic iron
oxide nanoparticles (SPION)] have been investigated as poten-
tial contrast agents for cancer imaging (Godin et al., 2011; Huang
et al., 2011). Gold and iron oxide nanoparticles (IONPs) in par-
ticular offer several advantages compared to conventional small
organic MRI and CT contrast agents (Godin et al., 2011; Huang
et al., 2011). For example, IONPs have a lower toxicity profile
when compared to gadolinium based contrast agents used in
current MRI (Boyer et al., 2010). These nanoparticles have the
potential to enhance the contrast between the delayed uptake
(hypoperfusion) of the hypovascular tumors when compared to
the normal parenchyma during the arterial and venous phase
with conventional radiology approaches (Erkan et al., 2012a,b).
Indeed, various nanoparticle systems have been generated with
enhanced longitudinal relaxation time (T1) and transverse relax-
ation time (T2) for high spatial resolution and simultaneous
extraction of physiological, molecular, and anatomical informa-
tion using MRI. Gadolinium-based contrast nanoparticles have
been investigated to enhance T1-weighted imaging; while vari-
ous iron oxides, alloyed and bimetallic ferrite nanoparticles have
been shown to be promising T2 contrast agents (Huang et al.,
2011). In a study by Kumagai et al. (2010) the authors designed
and synthesized a high-density pegylated-coated iron oxide-gold
core shell nanoparticle for MRI imaging. The nanoparticle was
approximately 25 nm in diameter. Systemic administration of
the nanoparticle to mice bearing a subcutaneous colon tumor
or an orthotopic pancreatic tumor resulted in its high accumu-
lation into tumor tissue and low non-specific accumulation in
the liver and spleen. In another example, extremely small sized
(<4 nm) IONPs have been used as T1 contrast agents with further
improvements in reducing non-specific toxicity and enhanced
properties for overcoming the commonly observed “blooming
effect” (a phenomenon observed which exaggerates the size of
a labeled area as well as blurs the image) of T2 contrast agents
(Kim et al., 2011). In addition, multifunctional nanoparticles
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or hybrid systems have also shown great promise. These nano-
materials possess greater signal amplification further improving
the diagnostics and imaging sensitivity, while also having the
capacity to be used as a therapeutic. For instance, Kirui et al.
(2013) reported the use of a gold-iron oxide hybrid nanopar-
ticle to image and treat colorectal tumors in mice. The iron
oxide enabled for MR imaging of the tumor, while the gold
allowed for photothermal therapy. To improve tumor imag-
ing and targeted therapy the authors conjugated an antibody
to the surface of the nanoparticle which recognized the A33
antigen which is expressed on the surface of colorectal tumor
cells (Kirui et al., 2013). Importantly, administration of the
hybrid nanoparticle to mice with xenografted colorectal tumors
showed highly effective tumor imaging and increased tumor cell
death when laser irradiation was applied (Kirui et al., 2013).
In another example, Kaida et al. (2010) demonstrated the use
of a supramolecular nanocarrier system which incorporated
a clinically approved gadolinium-based MRI imaging contrast
agent and a platinum anti-cancer drug (oxaliplatin). The authors
showed successful imaging and combined anti-tumor therapy
using the supramolecular nanoparticle in an orthotopic pan-
creatic cancer mouse model without any significant off-target
toxicity (Kaida et al., 2010). Moreover, the amount of gadolin-
ium delivered by the nanoparticle to the tumor was seven times
higher when compared to free-gadolinium alone (Kaida et al.,
2010). However, it is to be noted, that most nano-formulated
contrast agents depend on passive targeting to the tumor site
via the enhanced permeability and retention (EPR) effect (Cheng
et al., 2013). The EPR effect was first described in 1986 by
Matsumura andMaeda (1986) and is a result of rapid and uncon-
trolled angiogenesis during solid tumor growth which gives rise
to leaky and damaged vasculatures within the tumor microen-
vironment compared to normal tissue (Maeda et al., 2000).
This phenomenon allows for vascular extravasation of nanopar-
ticles from a wide size range (100–700 nm) to solid tumors.
However, it is to be noted that nanoparticles which enter the
solid tumor do not necessarily bind specifically to tumor cells,
and have the potential to be taken up by other cell types in
the tumor microenvironment (Olive et al., 2009; Erkan et al.,
2012a,b).
Nevertheless, despite potential pitfalls with passive
tumor targeting, nanotechnology has the ability to advance
molecular-targeted imaging in pancreatic cancer owing to the
ease of functionalizing nanoparticle surfaces with targeting
moieties (antibodies, aptamers, and small molecules) to provide
enhanced binding affinity and specificity toward the tumor. This
was recently illustrated in a study by Yang et al. (2009) which
demonstrated the use of multifunctional nanoparticles to target
a cell surface receptor urokinase plasminogen activator receptor
(uPAR) which is highly expressed in pancreatic cancer cells and
tumor stromal cells. Importantly, the nanoparticles enhanced
visualization of pancreatic tumors with a high level of sensitivity
in an orthotopic pancreatic cancer mouse model using either
non-invasive near-infrared optical imaging or MRI (Yang et al.,
2009). In another study, a peptide phage display library was used
to screen for small peptides which selectively bound to the sur-
face of pancreatic tumor cells in a genetically-engineered mouse
model of pancreatic ductal adenocarcinoma (Kelly et al., 2008).
Using this technology the authors identified a small peptide which
was able to distinguish the tumor cells from surrounding normal
pancreatic ductal cells. Furthermore, proteomic analysis revealed
that the peptide bound to plectin-1 (intermediate filament of
the cell cytoskeleton). The peptide was then conjugated to the
surface of magneto-fluorescent nanoparticles and in conjunction
with intravital microscopy and MRI imaging the nanoparticles
were able to selectivity detect small pancreatic tumors and
pre-cursor lesions with high sensitivity in the mouse model
(Kelly et al., 2008). This study highlights the potential of targeted
nanoparticles to allow for the visualization of molecular markers
that identify specific stages of pancreatic tumor development.
More recently, attempts have been made to identify potential
markers for the active targeting of pancreatic stroma. Directing
contrast agents to the stromal components of pancreatic cancer
may amplify contrast signals at both the tumor and precursor
lesion sites. For example, Erkan et al. (2007) showed that
periostin a secretory protein that accumulates in fibrotic areas is
exclusively produced by activated PSCs and is highly expressed in
pancreatic cancer compared to normal pancreatic tissue. Thus,
the exclusive expression of periostin in the pancreatic tumor
microenvironment may be a potential novel target for molecular
imaging of pancreatic cancer (Erkan et al., 2007). This concept
was recently illustrated by Eck et al. (2008) which took advantage
of the strong light scattering signal from gold nanoparticles. To
target tumor stroma the nanoparticles were conjugated with
antibodies directed against fibroblast activation protein-α which
is produced specifically by activated fibroblasts in tumor stroma
(Eck et al., 2008). Taken together, these studies highlight the
potential for the combined use of molecular markers which target
pancreatic cancer cells and/or the surrounding tumor stroma
and nanotechnology to improve the specificity and sensitivity of
current pancreatic cancer imaging modalities.
NANOMEDICINES AS A NOVEL CLASS OF THERAPEUTICS
FOR PANCREATIC CANCER
The design and synthesis of nanoparticles which can encapsulate
and deliver a diverse range of therapeutic compounds—ranging
from chemotherapy agents to DNA/RNA has received significant
attention in cancer research. Nanoparticles in the form of lipo-
somes and/or polymer-derived nanomaterials have been widely
used in a number of pre-clinical cancer models. Importantly,
these nanoparticles have shown great potential as highly efficient
delivery vehicles for chemotherapy drugs or RNA interference
(RNAi) inhibitors and are currently being evaluated in human
clinical trial (Blanco et al., 2011; Namiki et al., 2011; Schroeder
et al., 2011; Singh et al., 2012). A select number of examples for
the use of nanoparticles to deliver chemotherapy agents or RNAi
inhibitors are described in the following sections.
NANOPARTICLES AS DELIVERY VEHICLES FOR CHEMOTHERAPY
DRUGS
Many chemotherapeutic agents are associated with debilitat-
ing off-target toxicity, poor tumor bioavailability, and unfavor-
able pharmacokinetics. One strategy to overcome these chal-
lenges is the use of nanotechnology as efficient carriers for
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chemotherapeutic drugs. The rational design of nanoparticles for
chemotherapeutic drug delivery has enabled the improved solu-
bilization of the drug, as well as increased its stability and half-life
in circulation (Blanco et al., 2011; Pearce et al., 2012). In addi-
tion, nanoparticles encapsulated with chemotherapy agents are
able to avoid multi-drug resistant efflux pumps expressed on the
surface of most tumor cells (Blanco et al., 2011; Pearce et al.,
2012). The first nanoparticle-drug approved by the FDA (1995)
was “Doxil.” Doxil is a liposome with an approximate size of
100 nm in diameter which encapsulates the chemotherapy drug
doxorubicin (Barenholz). To improve tumor bioavailability the
liposome was modified to contain a small amount of polyethylene
glycol (PEG)-lipid to reduce the clearance of the nanoparticles
from the blood, and increase the plasma half-life of doxoru-
bicin. Indeed, encapsulation of doxorubicin within the liposome
was shown to significantly alter its pharmacokinetic and phar-
macodynamic properties leading to increased tumor uptake and
anti-cancer activity, along with a reduction in systemic off-target
toxicity (Barenholz, 2012). Today Doxil is used to treat a number
of different solid tumors, including platinum-resistant ovarian
cancer (Leamon et al., 2013).
Over the recent years, there have been attempts to develop
nanoparticle formulations of the chemotherapeutic agent gemc-
itabine. Indeed, gemcitabine has long been the first-line treatment
for patients with unresectable locally advanced or metastatic pan-
creatic cancer (Vincent et al., 2011). However, despite its use as a
first-line treatment, patient survival has only been extended by
6–12 weeks (Hidalgo, 2010). Hence, in an attempt to improve
the delivery of gemcitabine to pancreatic tumors as well as over-
come some of the acquired gemcitabine-resistant mechanisms
in pancreatic cancer cells nanoparticles have been used as a
delivery vehicle. Recently, Wonganan et al. (2013), Zhu et al.
(2013) demonstrated the potential of a nanoparticle encapsulated
with the pro-drug of gemcitabine [4-(N) stearoyl gemcitabine]
(GemC18) to overcome resistance associated with ribonecleotide
reductase subunit M1 overexpression in pancreatic cancer cells.
Interestingly, the authors showed that encapsulation of the gem-
citabine pro-drug into the nanoparticle allowed for a different
mode of entry into the cell which allowed the gemcitabine to
be hydrolyzed more efficiently to its active form compared to
the pro-drug alone (Wonganan et al., 2013; Zhu et al., 2013). In
another example, Lee et al. (2013) engineered IONPs to express
a uPAR-targeted moiety on their surface. Both pancreatic tumor
cells and the blood vessels within the tumor stroma have high
amounts of the uPAR receptor (Harvey et al., 2003). Themagnetic
IONPs also had gemcitabine attached via a lysosomally cleavable
tetrapeptide linker (Lee et al., 2013). Importantly, systemic deliv-
ery of the nanoparticle-gemcitabine complex significantly inhib-
ited the growth of orthotopically xenografted pancreatic tumors
in mice and allowed for the detection of residual tumors follow-
ing treatment using MRI (Lee et al., 2013). More recently, there
has also been interest in developing nanotechnology to improve
the delivery and efficacy of other chemotherapeutic agents which
can be delivered in combination with gemcitabine or used as
second-line treatment for pancreatic cancer. For example, Cabral
et al. (2013) synthesized micelle nanoparticles which were able to
self-assemble with the chemotherapeutic drug oxaliplatin. These
nanoparticles were designed to gradually release their contents
over time when only exposed to the tumor microenvironment.
Importantly, the authors demonstrated that repeated systemic
administration of the drug-loaded nanoparticles was able to sig-
nificantly reduce tumor growth as well as the incidence of metas-
tases in a clinically relevant transgenic mouse model of pancreatic
cancer. Therefore, this therapy may be beneficial for treatment
of patients with early-stage pancreatic cancer so as to prevent or
retard the development of metastases.
Another nanoparticle-bound chemotherapy agent which has
generated significant interest is albumin-bound paclitaxel known
as Nab-paclitaxel or Abraxane® (Abraxis Bioscience). A recent
phase I/II trial for pancreatic cancer demonstrated themaximum-
tolerated dose for Nab-paclitaxel in combination with gemc-
itabine (Von Hoff et al., 2011). The authors also reported an
improved overall survival in patients treated with nab-paclitaxel
plus gemcitabine (12.2 median months of overall survival) com-
pared to gemcitabine alone. Moreover, Nab-paclitaxel alone and
in combination with gemcitabine was shown to deplete pancre-
atic stroma in pancreatic cancer xenograft mouse models (Von
Hoff et al., 2011). Importantly, the depletion of stroma led to a
2.8 fold increase in the intratumoral concentration of gemcitabine
(Von Hoff et al., 2011). A recent phase III MPACT (Metastatic
Pancreatic Adenocarcinoma Clinical Trial) trial also showed that
the addition of Nab-paclitaxel with gemcitabine was not only
able to significantly improve the median survival of metastatic
pancreatic cancer patients (8.5 months) when compared to gem-
citabine treated only arm (6.7 months), but also significantly
reduced toxicities (neuropathy and neutropenia) commonly asso-
ciated with the cremaphor formulation used to dissolve paclitaxel
thereby, allowing for a higher paclitaxel dose to be delivered
(Ma and Hidalgo, 2013; Von Hoff et al., 2013). The authors also
reported an increase in peripheral neuropathy andmyelosuppres-
sion. However, these side-effects appeared to be reversible (Von
Hoff et al., 2013).
Finally, nanotechnology had also been used to improve
drug kinetics and tumor bioavailability, of a therapeutic agent
by directly targeting and ablating the tumor stroma. Indeed,
Provenzano et al. (2012) showed that the desmoplastic reaction
surrounding pancreatic tumor cells generated very high amounts
of interstitial fluid pressure along with the induction of vascu-
lar collapse (Provenzano et al., 2012). Systemic administration of
PEGylated human recombinant PH20 hyaluronidase (PEGPH20)
[an enzymatic agent that targets a critical component of the
desmoplastic stroma in pancreatic cancer known as hyaluronic
acid (HA)] (Provenzano et al., 2012) in a murine pancreatic can-
cer model, produced a marked decrease in tumor stroma which
correlated to a rapid and signi?cant decrease in interstitial tumor
pressure and increased tumor blood vessel lumen diameter.
Furthermore, when delivered in combination with gemcitabine
there was a strong anti-tumor effect compared to gemcitabine
alone (Provenzano et al., 2012). Collectively, these studies high-
light the advances in nanotechnology as highly effective carriers
for the passive and active delivery of chemotherapy drugs to
tumor cells in pre-clinical and clinical settings. In the future, nan-
otechnology which can therapeutically target the tumor stroma
to enable stroma depletion and tumor vascular normalization as
www.frontiersin.org January 2014 | Volume 5 | Article 2 | 5
McCarroll et al. Therapeutic potential of nanotechnology and pancreatic cancer
well as deliver therapeutics directly to the tumor cells may become
a highly effective novel treatment strategy for pancreatic cancer.
NANOPARTICLES AS DELIVERY VEHICLES FOR RNA INTERFERENCE
INHIBITORS
RNA interference (RNAi) based therapeutics are emerging as
an innovative and promising alternative over conventional sys-
temic treatments in terms of specificity, toxicity, and overcoming
multiple drug resistance. RNAi is an endogenous gene-silencing
mechanism that can cause the degradation of any mRNA, once
the RNA target sequence is known (Rana, 2007). In particu-
lar, short-interfering RNAs (siRNA) have gained attention due
to their ability to potently silence target gene expression both
in vitro and in vivo (Rana, 2007). siRNAs are processed double
stranded RNAs approximately 21 nucleotides in length, and are
involved in post-transcriptional gene silencing toward targeted
mRNAs. The RNA-induced silencing complex (RISC) located
within the cytoplasm of the cell act as a guide for the cleav-
age of mRNAs bearing a complementary sequence to the siRNA
(Rana, 2007). Once activated RISC can be recycled multiple times
to cleave additional mRNA targets (Rana, 2007). Importantly,
the introduction of chemically synthesized siRNAs into the cell
can activate this naturally-occurring mechanism, which can be
harnessed as a powerful gene therapy to suppress specific genes
associated with human disease, including cancer. However, deliv-
ery of siRNA to a target cell remains a challenge. The major
limitation of in vivo siRNA delivery is its instability and vul-
nerability to degradation in serum and inability to readily enter
a cell due to its high anionic (negative) charge (Baigude and
Rana, 2009). Nanoparticles in the form of liposomes, lipid poly-
mers, and dendrimers have been developed over the last decade
to act as highly effective siRNA delivery vehicles (Figure 1)
(Zimmermann et al., 2006; Baigude et al., 2007; Davis et al., 2010;
Su et al., 2011). Indeed, nanoparticles can be designed to self-
assemble with siRNA and protect it from serum degradation and
elimination from the body (Schroeder et al., 2010). Moreover,
nanoparticles can be tailored to possess multifunctional com-
ponents to allow for targeted siRNA delivery and efficient entry
to a specific cell type (Schroeder et al., 2010). The therapeutic
potential of nanoparticle-siRNA complexes to treat human dis-
ease was first reported by Zimmermann et al. (2006). In this study,
the authors used modified nanoparticles (liposomes) known as
Stable Nucleic Acid Lipid Particles (SNALP)s to deliver siRNA
targeting apolipoprotein B (apo B) (a protein involved in regu-
lating cholesterol metabolism) to non-human primates. A single
systemic administration of low clinically relevant amounts of
FIGURE 1 | Illustration showing some common non-viral nanoparticles
used as delivery vehicles for siRNA. A schematic diagram of non-viral
nanoparticle-siRNA delivery vehicles. (A) Liposomes which have been
modified with PEG chains and contain active targeting moieties on their
surface to improve tumor bioavailability. (B) Dendrimers which are highly
branched well-defined structures that complex with siRNA via electrostatic
interactions. (C) Cationic (positively charged) lipid polymers interacting with
negatively charged siRNA to form self-assembled nanoparticles.
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SNALP-siRNA complexes caused a significant reduction in apo
B mRNA and protein expression as well as a reduction in total
cholesterol (Zimmermann et al., 2006). The nanoparticle-siRNA
complexes were non-toxic and provided sustained knockdown of
apo B for up to 11 days (Zimmermann et al., 2006). SNALPs have
also been used to deliver siRNA to potently silence a gene involved
in promoting aggressive tumor growth in an orthotopic mouse
model of liver cancer (Judge et al., 2009). Collectively, these stud-
ies highlight the potential of using nanoparticle-siRNA complexes
as novel therapeutics to treat human disease in the clinic.
Recently there has been intense research effort into the devel-
opment of nanoparticles which contain targeting moieties (anti-
bodies, peptides) conjugated to their surface to deliver siRNA
specifically to tumor cells (Schroeder et al., 2010). Common
examples of cell surface targets used for delivery to tumor cells
include: transferrin receptor (TfR), folate receptor, and Arginine-
Glycine-Aspartic ligands. It is to be noted that these cell surface
receptors have been reported to be highly expressed in a number
of different tumor types (Allen, 2002; Daniels et al., 2006; Basile
et al., 2012). For instance, Pirollo et al. (2007) used nanoparti-
cles (liposomes) which contained a TfR-antibody on their surface
to complex siRNA against HER-2. Systemic delivery of the TfR-
targeting nanoparticles resulted in more siRNA being delivered
to pancreatic tumors in a murine xenograft model compared to
nanoparticles without the TfR antibody (Pirollo et al., 2007).
Moreover, delivery of the nanoparticle-siRNA complexes were
able to silence HER-2 expression in the pancreatic tumor cells
and increase sensitivity to gemcitabine (Pirollo et al., 2007).
Studies have also taken interest in targeting nanoparticles carry-
ing siRNA to the stroma of the pancreas. Of note, Ishiwatari et al.
(2013) were able to target activated PSCs using vitamin A-coupled
nanoparticles (liposomes) loaded with siRNA against collagen-
specific chaperone protein gp46 (VA-lip-siRNAgp46) (Ishiwatari
et al., 2013). VA-lip-siRNAgp46 complexes were actively taken up
by PSCs and subsequent silencing of gp46 expression correlated
to a significant decrease in PSC collagen secretion, which in turn
resolved pancreatic fibrosis in a rat model of chronic pancreatitis
(Ishiwatari et al., 2013). These promising findings point toward
the therapeutic potential of nanoparticle-siRNA complexes in
ablating the desmoplasia in pancreatic cancer.
Finally, siRNA-nanoparticle therapy based human clinical tri-
als are underway to evaluate the safety and efficacy of sys-
temic siRNA delivery using modified nanoparticles for the treat-
ment of cancer (Burnett et al., 2011; Davidson and McCray,
2011). Most notably, a phase I clinical trial involving systemic
siRNA administration to patients with solid tumors using a
TfR-guided cyclodextrin-nanoparticle (CALAA-01) showed great
promise (Davis et al., 2010). CALAA-01 is a nanoparticle-siRNA
complex that was used to silence anti-ribonucleotide reductase
(RRM2) in patients with metastatic melanoma. Results from
this study showed that systemic administration of CALAA-01
reduced RRM2 mRNA and protein levels in tumor tissue col-
lected via biopsy after adminstration (Davis et al., 2010). Another
landmark phase I study recently reported the use of nanopar-
ticles to simultaneously deliver two individual siRNAs targeting
vascular endothelial growth factor (VEGF) and kinesin spindle
protein (KSP) (Tabernero et al., 2013). The nanoparticle-siRNA
complex later renamed ALN-VSP was administered bi-weekly
(intravenously) and was found to be safe and well tolerated even
up to 23 months (Tabernero et al., 2013). Importantly, results also
showed disease control lasting more than 6 months and a com-
plete regression of liver metastases in a patient with endometrial
cancer (Tabernero et al., 2013).
CONCLUDING REMARKS
New strategies are needed to reduce the overall dismal prog-
nosis and increase survival of pancreatic cancer patients.
Nanomedicines offer great potential with benefits for diagnostics,
imaging, and therapeutics. As our knowledge of pancreatic cancer
becomes more complete, it is increasingly important for clin-
icians, biologists, and biochemical engineers to integrate novel
ideas for the treatment of pancreatic cancer. Developing nanopar-
ticle therapies based on the unique tumor microenvironment is
crucial to the delivery of clinically relevant amounts of active
therapeutics to the tumor site while by-passing various biologi-
cal barriers. As highlighted in this review nanoparticles could be
used to target tumor elements and stromal elements of pancre-
atic cancer. In summary, nanotechnology will have an important
role in realizing the goal for early detection and personalized pan-
creatic cancer treatment for patients at different stages of disease,
avoiding unnecessary toxicities associated with current treatment
regimes and increasing patient survival.
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